News
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine,
Pfizer (NYSE:PFE) and GSK (NYSE:GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to ...
A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...
The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...
Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, and adults 18 and older at increased risk of lower respiratory tract disease caused by RSV ...
US flu activity declined steadily again last week, with rates of influenza-like illness (ILI) dropping further and staying ...
Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...
A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback